Health Care • Biotechnology: Pharmaceutical Preparations
$1.31 ▼ -0.04
(-2.96%)
MKT CAP: $101.9M • VOL: 1.21M
52W L $1 52W H $2
ROARABLE / RQD
D • 45/100
PIOTROSKI
2 / 9
PMVP // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$86.2M | -$85.4M | -$80.1M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$77.7M | -$58.9M | -$69.0M |
| EBITDA (Normalized) | -$86.2M | -$84.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$73.6M | -$51.3M | -$55.7M |
| Capital Expenditures (CapEx) | $29.0K | $655.0K | — |
| Free Cash Flow (FCF) | -$73.6M | -$51.9M | -$55.7M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $38.0M | $40.9M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $104.7M | $176.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PMVP.